Surufatinib plus camrelizumab and mFOLFOX6 for advanced pancreatic cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of three drugs—surufatinib (a targeted therapy), camrelizumab (an immunotherapy), and a chemotherapy regimen called mFOLFOX6—as a second-line treatment for advanced pancreatic cancer. It's for people whose cancer progressed after first-line gemcitabine-based chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have metastatic pancreatic cancer (cancer that has spread to other parts of the body).
- You must have tried a first-line chemotherapy that included gemcitabine, and it stopped working or your cancer came back.
- Your overall health should be good enough to be up and about (ECOG score 0 or 1).
- You must have at least one tumor that can be measured on scans.
- You cannot have had prior immunotherapy (like PD-1/PD-L1 inhibitors) or anti-VEGF/VEGFR targeted therapy (such as bevacizumab).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs—surufatinib, chemotherapy (mFOLFIRINOX), and an immunotherapy (PD-1 inhibitor)—given before surgery to shrink tumors and improve outcomes for people with pancreatic cancer that is high-risk or borderline resectable.
This trial tests if adding two targeted drugs (surufatinib and serplulimab) to standard chemotherapy can shrink locally advanced pancreatic cancer enough to allow surgery. It may help people whose cancer hasn't spread and who haven't had prior treatment.
This Phase 2 study tests a combination of anti-cancer drugs (surufatinib, immunotherapy, and capecitabine) to treat cancer that has spread to other parts of the body. It’s for people whose small intestine or appendix adenocarcinoma has progressed after earlier treatment, aiming to shrink tumors and improve control of the disease.
This trial tests a combination of chemotherapy, radiation, and two targeted drugs (surufatinib and tislelizumab) for people with stage III non-small cell lung cancer that cannot be surgically removed. The goal is to see if this approach works better than standard treatment.
This trial tests a new combination of treatments for people with advanced esophageal cancer that can't be removed by surgery. It uses a targeted therapy called surufatinib along with chemo-immunotherapy and radiation to see if it can shrink the tumor before further treatment.
This trial studies whether a combination of surufatinib and immunotherapy (camrelizumab, plus an “AS” medicine) can slow or shrink advanced pancreatic cancer that has spread. It is for people starting treatment for advanced disease for the first time and may help those who have measurable tumors and meet safety test limits.
Hear when a new Advanced Pancreatic Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.